Ergomed to acquire orphan drug CRO for €5.7m

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/Hankimage9)
(Image: iStock/Hankimage9)

Related tags: Orphan drug, Pharmacology, Rare disease

Ergomed is bolstering its orphan drug development services with its acquisition of PSR Group BV in a deal worth up to €5.7m ($6.69m) – which will position the company to be a “global player” in the area, says CEO.

According to the specialized pharmaceutical services and drug development company, the acquisition of the Dutch contract research organization (CRO) will complement its current expertise in orphan drug development.

Ergomed CEO Dr. Dan Weng told Outsourcing-Pharma.com the orphan drug sector has been a focus for the company – and it is growing.

The combined specialist expertise of PSR and Ergomed and a geographical reach which includes the MENA region will benefit customers developing drugs for orphan diseases​,” explained Weng.

Ergomed’s unique site management and study physician support operation will enable PSR and Ergomed to provide a full scope of services to customers on drug development services for rare diseases​,” he added.

Following the acquisition, PSR’s orphan drug development business will continue under the PSR brand and will focus on its two divisions: PSR Orphan Experts and PSR Pharma Resource.

As for next steps, Weng explained Ergomed will continue to grow its orphan drug services globally.

“The acquisition is in line Ergomed’s continuous growth strategy and will position the company to become a global player in orphan drug development services,” ​he said.

Related topics: Clinical Development

Related news

Show more

Follow us

Products

View more

Webinars